Chronic Lower Back Pain Market

1
(No Transcript)
2
Chronic Lower Back Pain
Chronic Lower Back Pain persists for 12 weeks or
longer, even after an initial injury or
underlying cause of acute low back pain has been
treated. Low back pain is very common and at one
point everyone may have faced this problem.
The exact cause of lower back pain is unknown.
Lower back pain that is long-term is called
chronic low back pain, this condition might
originate from an injury, disease, or stress on
different structures of the body, and pain may
vary significantly.
Pain severity may form bi-dimensional or
one-dimensional scale depending on the specific
instruments tested. High inter-correlations
between pain-intensity measures and pain-related
disability measures support a unitary construct
of pain severity.
Various scales are used by experts in order to
assess the severity of pain in CLBP patients, two
of the most widely used are Visual Analogue Scale
(VAS) and Verbal Rating Scale (VRS).

• DelveInsight 2019 All rights reserved

3
CLBP Epidemiology
Chronic Lower Back Pain total prevalent
population was observed to be 73,802,461 in 2017
in the 7MM that is expected to increase during
the study period i.e. 2017-2028.
The total CBLP diagnosed prevalent population in
the 7MM was assessed to be 44,281,476 in 2017.
CLBP prevalence
CLBP PREVALENCE
The highest CBLP
diagnosed prevalence was more than 20 million
cases in 2017 in the United States.
CLBP prevalence
A higher percentage of CBLP diagnosed prevalence
was observed for females as compared to males in
all the 7MM countries, except Japan, wherein
males occupy a larger patient pool than females.
CLBP OCCURENCE

• DelveInsight 2019 All rights reserved

4
CLBP Market
Chronic Lower Back Pain market size in the 7MM is
expected to grow at a CAGR of 4.84 for the study
period (2017- 2028).
CLBP is mostly diagnosed in the age group of
40-69. Moreover, it has been observed that
moderate to severe are the majorly diagnosed CLBP
patients.
With the launch of the effective therapies, CBLP
market is going to rise that will introduce USD
623.19 million in 2022 to the overall CBLP
therapies market.
CLBP current pharmacological treatments do not
meet the needs of all patients. NSAIDs, opioids,
muscle relaxants, antidepressants,
anticonvulsants, muscle relaxants, and others
have only temporary efficacy in general, with
concerns for side effects related to long-term
use.
CLBP current market size is entirely dependent on
supportive treatment regimens, along with the
drugs that have been approved to treat
comorbidities associated with CLBP.

• DelveInsight 2019 All rights reserved

5
CLBP Emerging Drugs Companies
01
Drug- Tanezumab Company- Pfizer
02
Drug- Fasinumab Company- Teva pharmaceutical
03
Drug- NKTR-181 Company- Nektar Pharmaceuticals
04
Drug- GRT6005 Company- Grünenthal GmbH

• DelveInsight 2019 All rights reserved

6
Complete Information
For complete information on
Chronic Lower Back Pain Market Insights,
Epidemiology Market Forecast-2028 please
click the link below
CLICK HERE
OR
Write Us At 
info_at_delveinsight.com

• DelveInsight 2019 All rights reserved

7
About DelveInsight
1
2
3

• DelveInsight 2019 All rights reserved

8
Services by DelveInsight
PharmDelve
Forecasting
Opportunity Assessment
Consulting
Report Store
Market Intelligence
Competitive Analysis
Pipeline

• DelveInsight 2019 All rights reserved

9
Contact Us
info_at_delveinsight.com
91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight

• DelveInsight 2019 All rights reserved

10
Pompe Disease
9